Criteria for selecting who can enroll in multiple myeloma clinical trials may exclude patients from minority groups

Numerous studies have shown that people from racial and ethnic minority groups are underrepresented in clinical trials of new medical treatments for multiple myeloma. A study published today in the Blood Journal suggests that, for clinical trials of new treatments for multiple myeloma (a type of blood cancer), one reason for this underrepresentation may be that the parameters set to determine who can—and cannot—enroll in trials disproportionately exclude minority patients.

A simple antibacterial treatment can solve a severe skin problem caused by radiation therapy

Acute radiation dermatitis (ARD)—characterized by red, sore, itchy or peeling skin—affects up to 95% of people undergoing radiation treatment for cancer. Severe cases can cause significant swelling and painful skin ulcers that can severely impair quality of life, yet little is known about why this condition occurs and no standardized treatments for preventing severe ARD have been widely adapted.